Holen Sie sich die Stockscreener-App
16.31
0.12%
-0.02
Handel nachbörslich:
16.31
Schlusskurs vom Vortag:
$16.33
Offen:
$16.15
24-Stunden-Volumen:
205.91K
Relative Volume:
2.21
Marktkapitalisierung:
$238.87M
Einnahmen:
$166.88M
Nettoeinkommen (Verlust:
$-74.18M
KGV:
-10.66
EPS:
-1.53
Netto-Cashflow:
$1.14M
1W Leistung:
-4.95%
1M Leistung:
-5.06%
6M Leistung:
-37.22%
1J Leistung:
-26.76%
1-Tages-Spanne:
$15.96
$17.04
1-Wochen-Bereich:
$15.82
$17.30
52-Wochen-Spanne:
$15.82
$29.11
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie ANIK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
16.31 | 238.87M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-01 | Bestätigt | Barrington Research | Outperform |
| 2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
| 2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Eingeleitet | Stephens | Overweight |
| 2021-07-16 | Eingeleitet | UBS | Neutral |
| 2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Eingeleitet | BWS Financial | Sell |
| 2019-09-24 | Bestätigt | Barrington Research | Outperform |
| 2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
| 2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Bestätigt | Barrington Research | Outperform |
| 2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
Fmr LLC Acquires 4,996 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet - Simply Wall St
Anika Therapeutics stock hits 52-week low at $15.99 - Investing.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update - MarketBeat
Knee Osteoarthritis Market Projected CAGR 12.5% Dynamics - openPR
Joint Pain Injection Market Expected to Reach Prominent Growth - openPR
ANIK (Anika Therapeutics) Net Issuance of Preferred Stock : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.
Anika Therapeutics to Present at Three Major Healthcare Investor Conferences in December | ANIK Stock News - StockTitan
Anika To Participate in December 2024 Investor Conferences - GlobeNewswire
Orthopedic Regenerative Surgical Products Market to Witness - openPR
Joint Pain Injection Market Size, Share, Trends, - openPR
New Strong Sell Stocks for November 11th - Yahoo Canada Finance
Orthobiologics Market Size, Growth, Opportunities 2024-2032 | - openPR
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts - TipRanks
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA - MarketBeat
Anika Therapeutics Announces Third Quarter Financial ResultsOn October 31, 2024, Anika Therapeutics, Inc. released a press statement unveiling its financial outcomes for the third quarter concluding on September 30, 2024. As per the report - Defense World
Viscosupplementation Market Report Analysis, Growth - openPR
Anika Therapeutics (NASDAQ:ANIK) Downgraded to Hold Rating by StockNews.com - MarketBeat
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call Transcript - Insider Monkey
Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $25.00 - Defense World
Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring By Investing.com - Investing.com South Africa
Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring - Investing.com
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Anika Therapeutics (NASDAQ:ANIK) Given New $25.00 Price Target at Barrington Research - MarketBeat
Anika Therapeutics (NASDAQ:ANIK shareholders incur further losses as stock declines 30% this week, taking five-year losses to 72% - Simply Wall St
Anika: Q3 Earnings Snapshot - New Haven Register
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance UK
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline - GuruFocus.com
Anika Therapeutics divests Arthrosurface, eyes Parcus sale - Investing.com India
Anika Therapeutics Focuses on Core Growth Amid Restructuring - TipRanks
Anika Reports Third Quarter 2024 Financial Results - GlobeNewswire
Anika Therapeutics divests Arthrosurface, eyes Parcus sale By Investing.com - Investing.com Canada
Anika Therapeutics stock hits 52-week low at $18.67 - Investing.com
ANIKAnika Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Phoenix Brio, Incorporated acquired Arthrosurface, Inc. from Anika Therapeutics, Inc. for $10 million. - Marketscreener.com
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics - PR Newswire
Anika Therapeutics stock hits 52-week low at $18.67 By Investing.com - Investing.com UK
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical - citybiz
Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Anika Therapeutics Inc (ANIK) Q3 2024: Everything You Need To Kn - GuruFocus.com
(ANIK) Proactive Strategies - Stock Traders Daily
Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 61% over the last five years - Yahoo Finance
Anika Therapeutics, Inc. (NASDAQ:ANIK) Sees Significant Decline in Short Interest - MarketBeat
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anika Therapeutics Inc-Aktie (ANIK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '24 |
Option Exercise |
0.00 |
64,480 |
0 |
166,228 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '24 |
Option Exercise |
0.00 |
16,809 |
0 |
35,245 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '24 |
Option Exercise |
0.00 |
5,856 |
0 |
11,838 |
| Levitz Michael L | EVP, CFO, Treasurer |
Mar 11 '24 |
Option Exercise |
0.00 |
19,201 |
0 |
49,565 |
1.61%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):